madman
Super Moderator
Dr. Ranjith Ramasamy and DR. Fernando Borges talk about testosterone, obesity, erectile dysfunction, infertility, stem cells, regenerative energies. PRP, exosomes, peptides, research. Covid19.
A nice and rich discussion about the future and perspectives.
Special participation of Felipe Veiga, a prodigy high school. student.
The Future of Men's Sexual Health: A Conversation with Dr. Ranjith Ramasami
From regenerative medicine and AI to the global testosterone crisis, one of andrology's brightest minds shares his vision for where the field is headed
When Dr. Fernando Boures, a Brazilian urological surgeon completing a fellowship in regenerative andrology in Dubai, sat down with Dr. Ranjith Ramasami, the conversation that followed was less a formal interview and more a meeting of minds at the frontier of men's health medicine. With over 500 indexed publications, more than 7,000 citations, and a reputation for paradigm-shifting research — including being among the first to document COVID-19's impact on male fertility and erectile function — Dr. Ramasami represents a new generation of andrologists: clinically rigorous, scientifically bold, and deeply aware that the field is on the cusp of transformation.
A Journey from India to the Cutting Edge of Andrology
Dr. Ramasami grew up in India before his family relocated to the United States, where he completed his undergraduate studies at Rutgers and medical training at Cornell. His fellowship at Baylor College of Medicine sparked a passion for translational research — the art of moving discoveries from the laboratory bench to the patient bedside.
"Within urology, I felt andrology and male fertility and sexual medicine was sort of an afterthought," he recalls. "People didn't know much about it. People didn't want to go into it. The smart and bright ones in urology were not entering into that specialty." That vacuum, rather than discouraging him, became an invitation. "Trying to help men with quality of life — both their sexual life and reproductive life — was equally important compared to just the quantity of life."
His most recent move — from Miami to Dubai — was driven by both family considerations and scientific opportunity. In the UAE, regulatory frameworks allow stem cell and exosome therapies that remain restricted in the United States, opening new avenues for research into severe male infertility and erectile dysfunction.
COVID-19 and the Study That Changed Public Health
Among the research milestones Dr. Ramasami is most proud of is a study published in JAMA — viewed over one million times — that demonstrated COVID-19 vaccines do not impair sperm parameters. The work came at a critical moment when public fear about vaccine-related infertility was threatening vaccination rates worldwide.
"Before we got the vaccine, COVID was identified in many organs," he explains. "I asked myself: if COVID is causing endothelial dysfunction, it can be present in the reproductive organs, because there is endothelium both in the testis and the penis." His team was among the first to show the virus could persist in both organs long after infection cleared, causing erectile dysfunction and male infertility. When the vaccine arrived, the public understandably feared it would do the same. "The vaccine is just a small piece of the mRNA of the actual whole virus. It did not have the entire elements that would cause male infertility." The study launched in tandem with the vaccine rollout — providing reassurance at precisely the moment it was needed most.
The Global Testosterone Crisis: More Than Low T
The conversation turns to what Dr. Ramasami calls one of the most under-discussed crises in modern medicine: the sharp global decline in testosterone levels and sperm counts, particularly among adolescents and young adults.
"Obesity will continue to remain a problem, at least through our generation," he says, citing not just adult obesity but the less-discussed epidemic among 12-to-21-year-olds. "During this critical phase right after puberty, if obesity is present, there will be lifelong consequences. The testes need to be cooler for both sperm production and testosterone production. Both are hampered because of obesity and functional hypogonadism."
Environmental factors compound the problem. Endocrine-disrupting chemicals, microplastics, pesticides, and agricultural antibiotics are likely contributors to a decline in testosterone that cannot be explained by genetics alone. "Such a sharp decline in testosterone levels and sperm counts that have happened over the last 10 to 20 years cannot be explained by genetics," he says plainly. "It has to be explained by environmental factors."
When asked whether investing in obesity drugs or making healthy food more affordable would be more impactful, his answer is unequivocal: "Obesity medicines are just a band-aid. Changing the paradigm of how we make healthy food less expensive — that's a potential cure."
Regenerative Medicine: Where the Field Is Heading
Since the introduction of Viagra in the late 1990s and Cialis in the early 2000s, there have been no major pharmacological breakthroughs in erectile dysfunction treatment. Dr. Ramasami believes the next wave of progress will come not from new drugs, but from regenerative therapies.
The current landscape, as he describes it, moves through three tiers of evidence. Shockwave therapy — high-energy ultrasound that improves blood flow — now has Level 1 evidence supporting its use in mild vasculogenic ED and is recognized in European Association of Urology guidelines. Platelet-rich plasma (PRP) has a growing body of data suggesting safety, with mixed results on efficacy. Stem cells and exosomes are newer still, with promising animal data and early human trials focused primarily on safety.
"Men want to have the natural ability to have sex as opposed to relying on pills the entire time," he observes. "There is a slow but steady paradigm shift towards thinking about regenerative therapies early on in the course of a man with erectile dysfunction."
In Dubai, he is leading the RISE study (Regenerative Injection of Stem cells and Exosomes for erectile dysfunction), which follows a protocol of five shockwave therapy sessions before injecting either stem cells — for men with severe ED, including post-prostatectomy patients — or exosomes for mild-to-moderate cases. A parallel program, the FERTILE study, investigates stem cell injections directly into testicular tissue for men with azoospermia who have failed surgical sperm retrieval.
His caution is notable. When discussing who should offer these therapies, he is blunt: "Patients are caught in a quagmire — not being able to access correct treatments, not being able to afford them, and not being able to receive them from a physician who actually knows how to treat erectile dysfunction as a disease, rather than offering these therapies for money."
The Problem with PDE5 Inhibitors Used Without Medical Oversight
The widespread availability of sildenafil and tadalafil — with or without prescriptions in many countries — concerns Dr. Ramasami for reasons beyond simple access. Young men using these drugs when they don't truly need them, or when their ED is primarily psychogenic, are masking an opportunity for real diagnosis.
"Erectile dysfunction is a true diagnostic marker of underlying endothelial dysfunction — potential future heart attacks, diabetes, cardiovascular disease," he explains. A young man who takes a pill and achieves an erection may never receive the cardiovascular workup that could have detected hypertension or insulin resistance years before a serious event. Worse, early dependency may mean these drugs stop working precisely when they're most needed later in life, leaving patients with fewer options.
GLP-1 Agonists, Peptides, and the Off-Label Frontier
On the explosion of GLP-1 agonist use — semaglutide, tirzepatide, and the not-yet-FDA-approved retatrutide — Dr. Ramasami is measured. These drugs have "revolutionized" obesity treatment, he says, but access without medical supervision carries real risks. "We don't have enough safety data on these. We certainly don't have long-term safety data." His recommendation: pursue them through a physician, monitor carefully, and use the period of weight loss to build the behavioral changes that can sustain the results.
Regarding peptides more broadly, he sees them as "a very nice bridge between oral supplements and hormonal therapies." Two stand out for their FDA-approved status in related indications: bremelanotide (PT-141), approved for hypoactive sexual desire disorder in women and increasingly used off-label for low libido in men with normal testosterone; and tesamorelin, approved for HIV-related lipodystrophy but useful for reducing central adiposity. More approvals, he predicts, are coming.
AI in Andrology: Promise Without Hype
Dr. Ramasami is already using AI in clinical practice. His team employs AI-assisted sperm identification in testicular tissue during microsurgical sperm retrieval — a technically demanding process where the technology meaningfully improves efficiency and success rates. Research into AI-guided extended sperm search in ejaculate samples is also underway.
But his view of AI's role is carefully bounded. "AI is not an inventor. Humans need to invent. AI can help discover — it can help identify the best patients that will respond to therapies." The most valuable application, in his view, is personalized treatment matching: determining which patients will respond to which therapies before exposing them to expensive, time-consuming, or emotionally fraught interventions.
"We are not in need of more therapies," he says with conviction. "We are in need of figuring out which therapies work best for which patients."
Building the Next Generation: The UnderRegen Project
The interview concludes with a discussion of the UnderRegen Educational Project — an initiative Dr. Boures is launching in Brazil to formalize training in regenerative sexual medicine. Dr. Ramasami is an enthusiastic partner and board member.
"We need to create awareness among urologists and among doctors who are truly passionate about treating erectile dysfunction as a whole," he says. "Offering the entire armamentarium — from pills, injections, and vacuum pumps to regenerative therapies — before considering penile implants."
His concern is that the field is currently populated, in many markets, by practitioners who are not specialists in erectile dysfunction but who offer regenerative treatments because they can — and because they are lucrative. Education that builds genuine expertise, with appropriate patient selection and realistic expectations, is the antidote.
He envisions andrology evolving into a comprehensive men's health specialty over the next decade — one focused on longevity, hormonal optimization, metabolic health, and regeneration, not simply managing symptoms with pills. "We're going to be focused on trying to optimize hormones, optimize blood levels, rather than just treat the blood tests," he says. "And I think with that approach, some of these diseases may solve on their own with just a little bit of help."
A Legacy Built on Firsts
When asked what legacy he hopes to leave, Dr. Ramasami's answer is both humble and ambitious: "I've always wanted to be the first to do something. He was the first to — and you can fill in whatever blank you want."
For patients around the world navigating declining testosterone, erectile dysfunction, infertility, and the confusion of an unregulated supplement and peptide marketplace, clinicians like Dr. Ramasami represent something increasingly rare: a scientist willing to operate at the edge of evidence, guided by rigor rather than commerce, and genuinely motivated by converting that binary zero — no child, no erection, no hope — into a one.
This article was adapted from a podcast interview conducted by Dr. Fernando Boures in Dubai.
Last edited by a moderator:
